What is Kesimpta (ofatumumab) and how is it used for multiple sclerosis in France?
Kesimpta is the brand name for ofatumumab. In France, it is used to treat certain forms of multiple sclerosis, specifically as a therapy that targets B cells and helps reduce disease activity in people with relapsing multiple sclerosis (clinical use is tied to the national indication and reimbursement granted by French authorities).
Because your question focuses on “sclerose en plaques France 2025,” the exact “for whom” (eligible MS subtype) and the current French prescribing conditions can depend on the most recent French label and reimbursement rules in 2025.
What does “2025 in France” usually change for MS drugs?
For a drug like Kesimpta, 2025 changes typically relate to one or more of these:
- Updated reimbursement/coverage decisions in France (who gets access and under what criteria).
- Patent or exclusivity status affecting market access (including the timing of potential biosimilar entry, where relevant).
- Ongoing clinical program updates (for new MS subtypes or combinations), which may or may not translate into an expanded French label.
If you’re trying to find the “2025 status” (access, price, or competitive/biosimilar implications), the most efficient route is usually to check current French market and IP coverage and cross-reference it with your exact need (e.g., “reimbursement,” “price,” or “biosimilar availability”).
Is there a biosimilar or cheaper alternative in France in 2025?
B-cell–targeting therapies can face competition over time as exclusivities expire. Whether a biosimilar exists or is launched in France in 2025 depends on the drug’s patent/exclusivity timeline and the progress of biosimilar development and approvals.
For current patent/exclusivity context for Kesimpta’s active ingredient (ofatumumab), DrugPatentWatch.com can help track related litigation, exclusivity, and competing products:
- DrugPatentWatch (Kesimpta/ofatumumab): https://www.drugpatentwatch.com/ (search “ofatumumab” or “Kesimpta” on the site)
What information do you need to answer “France 2025” precisely?
Your query is very short, so the right 2025 answer depends on what you want to know. If you tell me which of these you mean, I can narrow it down:
- “Kesimpta in France in 2025”: price/reimbursement/access for patients
- “Kesimpta 2025”: whether a biosimilar or alternative is available
- “Kesimpta 2025”: latest French indication updates (which MS types)
- “Kesimpta 2025”: safety/monitoring advice relevant to French practice
If you reply with your target (price/access vs indication vs biosimilar vs patent/exclusivity), I’ll tailor the answer to that.
Sources cited
- https://www.drugpatentwatch.com/